Acute promyelocytic leukemia (APL), once described as the form of leukemia with the highest mortality, is now the most potentially curable subtype of adult acute myeloid leukemia. A brief review of the history of APL will describe the advances in research and clinical practice and their impact on patient outcomes. Oncology nurses should familiarize themselves with the nuances of APL because of the critical role nurses play in providing support for patients. This article provides an overview of APL, including the epidemiology and pathophysiology that distinguishes APL from other types of acute leukemia.

Clinical presentation and diagnostic workup for patients suspected of having APL will be reviewed, as will the treatment course. Nursing implications and management will be provided related to potential treatment complications specific to APL, including coagulopathies, differentiation syndrome, and QT prolongation with the use of arsenic trioxide, as well as several complications that can occur in any patient with leukemia, such as infection, hyperleukocytosis, tumor lysis, and increased intracranial pressure.

At a Glance

- **Acute promyelocytic leukemia (APL)** was previously considered a highly lethal form of acute myeloid leukemia (AML) but, because of research and drug development, is now the most curable subtype of adult AML.
- APL is pathologically different from other types of AML because of its specific morphology and abnormality on chromosomes 15 and 17.
- The complications of coagulopathy, differentiation syndrome, and QT prolongation are seen more commonly in patients diagnosed in APL compared to other types of leukemia.
- The complications of coagulopathy, differentiation syndrome, and QT prolongation with the use of arsenic trioxide, as well as several complications that can occur in any patient with leukemia, such as infection, hyperleukocytosis, tumor lysis, and increased intracranial pressure.

Deborah Kirk Walker, DNP, FNP-BC, AOCN®, and Jeanne Held-Warmkessel, MSN, RN, AOCN®, ACNS-BC, are participants in the Clinical Journal of Oncology Nursing (CJON) Writing Mentorship Program. The authors take full responsibility for the content of the article. Held-Warmkessel received an honorarium from the Oncology Nursing Society for her role as a mentor in the CJON Writing Mentorship Program. The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias. No financial relationships relevant to the content of this article have been disclosed by the independent peer reviewers or editorial staff. (Submitted December 2009. Revision submitted May 2010. Accepted for publication June 3, 2010.)

Digital Object Identifier:10.1188/10.CJON.747-759